| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.10.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.10.2025 | 816 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 23.10.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.10.2025.ISIN NameCA33564P1036 FIRST... ► Artikel lesen | |
| 23.10.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 23.10.2025 | 338 | Xetra Newsboard | Das Instrument 1AU FR0012789667 AMPLITUDE SURGIC. EO -,01 EQUITY wird cum Kapitalmassnahme gehandelt am 23.10.2025 und ex Kapitalmassnahme am 24.10.2025 The instrument 1AU FR0012789667 AMPLITUDE SURGIC.... ► Artikel lesen | |
| 13.10.25 | Amplitude Surgical SA: Results of the Simplified Tender Offer | 278 | Business Wire | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME), the French leader in surgical technologies for lower limb orthopedics.
On 10 October 2025, the... ► Artikel lesen | |
| 10.10.25 | XFRA 1AU: AUSSETZUNG/SUSPENSION | 395 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMPLITUDE SURGIC.... ► Artikel lesen | |
| 30.07.25 | XFRA 1AU: WIEDERAUFNAHME/RESUMPTION | 246 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| AMPLITUDE SURGICAL Aktie jetzt für 0€ handeln | |||||
| 29.07.25 | Zydus Announces Completion of the Acquisition of an 85.6% Stake in Amplitude Surgical and Upcoming Filing of a Simplified Tender Offer | 431 | Business Wire | Regulatory News:
Zydus Lifesciences Limited1 ("Zydus"), on March 11, 2025, entered into agreements with PAI and two minority shareholders of Amplitude Surgical (Paris:AMPLI) to acquire blocks of... ► Artikel lesen | |
| 29.07.25 | XFRA 1AU: AUSSETZUNG/SUSPENSION | 262 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMPLITUDE SURGIC.... ► Artikel lesen | |
| 29.07.25 | Amplitude Surgical - Suspension of Listing | 461 | Business Wire | Regulatory News:
Amplitude Surgical company has requested Euronext to suspend the listing of its shares (ISIN: FR0012789667, Ticker: AMPLI, eligible PEA-PME) on Euronext market with effect as from... ► Artikel lesen | |
| 24.07.25 | Amplitude Surgical - Consolidated annual revenue of €110.8 million, up +5.7% at constant exchange rates | 327 | Business Wire | Business growth of +3.8% at constant exchange rates in the fourth quarter of the 2024-25 financial year and of +5.7% for the full year
Strong momentum in France: revenue up +4.8%
Solid... ► Artikel lesen | |
| 25.04.25 | Zydus Lifesciences Limited Signs Purchase Agreement with PAI Partners and Other Shareholders to Acquire a Majority Stake in Amplitude Surgical SA | 443 | Business Wire | Regulatory News:
Amplitude Surgical SA (Paris:AMPLI):
Following the joint announcement of March 11, 2025, Zydus Lifesciences Limited ("Zydus") and Amplitude Surgical SA (Paris:AMPLI) ("Amplitude")... ► Artikel lesen | |
| 17.04.25 | Amplitude Surgical - 9-Months Consolidated Sales for FY 2024-25 of €83.8m, up +6.4% at Constant Exchange Rates | 388 | Business Wire | Sales up +6.6% at constant exchange rates in Q3 FY 2024-25
Consolidated sales for 9 months up+ 6.4% at constant exchange rates to €83.8m
Good momentum in France: sales up +4.7% over... ► Artikel lesen | |
| 17.04.25 | Zydus Lifesciences Limited announces the execution of undertakings to tender as part of its envisaged tender offer for Amplitude Surgical SA shares | 366 | PR Newswire | AHMEDABAD, India and PARIS, April 17, 2025 /PRNewswire/ -- Following the announcement of its envisaged tender offer on March 11, 2025, Zydus Lifesciences Limited announces the execution of... ► Artikel lesen | |
| 17.04.25 | Amplitude Surgical Has Been Informed by Zydus Lifesciences Limited of the Execution of Undertakings to Tender as Part of Its Envisaged Tender Offer for Amplitude Surgical SA Shares | 332 | Business Wire | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible).
Following the announcement of the envisaged tender offer on March 11, 2025 of Zydus Lifesciences Limited... ► Artikel lesen | |
| 26.03.25 | Amplitude Surgical Announces H1 2024-25 Results: 51.5 M€ Sales and 13.1 M€ EBITDA | 522 | Business Wire | Consolidated sales of €51.5m, up 6.3% at constant exchange rates
EBITDA up 10.6% to €13.1 million, EBITDA margin 25.4%
Current operating income of €6.0 million
Cash position... ► Artikel lesen | |
| 12.03.25 | XFRA 1AU: WIEDERAUFNAHME/RESUMPTION | 317 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 11.03.25 | XFRA 1AU: AUSSETZUNG/SUSPENSION | 305 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMPLITUDE SURGIC.... ► Artikel lesen | |
| 11.03.25 | Zydus Enters Exclusive Negotiations with PAI Partners and Other Shareholders to Acquire a Majority stake in Amplitude Surgical, France | 480 | Business Wire | Completion of the transaction to be followed by mandatory simplified tender offer
Zydus has entered into exclusive negotiations to acquire a controlling shareholding in Amplitude Surgical,... ► Artikel lesen | |
| 20.02.25 | Amplitude Surgical - 1st Half-year 2024-25: Consolidated Sales of €51.5m, +6.3% at Constant Exchange Rates | 410 | Business Wire | Consolidated sales of €51.5 million, up+ 6.3% at constant exchange rates
Good sales growth in France at +4.6%
Strong growth in international business thanks to subsidiaries, with... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORGANON | 7,110 | -1,28 % | Organon & Co.: Organon schließt die Veräußerung des JADA-Systems an Laborie ab | Organon (NYSE: OGN), ein globales Gesundheitsunternehmen mit der Mission, wirkungsvolle Medikamente und Lösungen für einen gesünderen Alltag bereitzustellen, gab heute den erfolgreichen Abschluss... ► Artikel lesen | |
| ENVUE MEDICAL | 3,230 | 0,00 % | ENvue Medical, Inc. - 8-K, Current Report | ||
| PROCEPT BIOROBOTICS | 28,960 | 0,00 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| PROGYNY | 23,870 | 0,00 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,270 | 0,00 % | BrightSpring Health stock price target raised to $46 by TD Cowen | ||
| ALIGNMENT HEALTHCARE | 22,540 | 0,00 % | Alignment Healthcare (ALHC) Drops 12% on Medicare Flat Funding | ||
| SIEMENS HEALTHINEERS | 42,250 | +0,48 % | HV-Termine: Hauptversammlungen bei CGRE, Healthineers, q.beyond, Schott, Siemens, Stabilus, ThyssenKrupp, TUI | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 38,170 | +1,98 % | DEUTSCHE BANK RESEARCH stuft FMC FRESENIUS MEDICAL CARE AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Fresenius Medical Care (FMC) vor den anstehenden Quartalszahlen von 46 auf 44 Euro gesenkt und die Einstufung auf "Hold" belassen.... ► Artikel lesen | |
| GENEDX | 96,13 | 0,00 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| HEARTFLOW | 29,890 | 0,00 % | Heartflow: Wells Fargo startet Coverage mit "Overweight" und Kursziel von 38 $ | ||
| CARL ZEISS MEDITEC | 27,840 | -0,71 % | BERNSTEIN RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat Carl Zeiss Meditec von "Outperform" auf "Market-Perform" abgestuft und das Kursziel von 50,55 auf 31,00 Euro gekappt. Nach der... ► Artikel lesen | |
| FRESENIUS | 47,840 | +2,51 % | EQS-PVR: Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
26.01.2026 /... ► Artikel lesen | |
| RXSIGHT | 8,710 | 0,00 % | RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer | ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 23,220 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| BETA BIONICS | 13,820 | 0,00 % | Beta Bionics, Inc. - 8-K, Current Report |